AGARWALEYE Dr. Agarwal's Health Care Q3 FY25 results (Oct–Dec 2024) and concall
Dr. Agarwal's Health Care Limited reported a strong Q3 FY25, with revenue growing 28.6% YoY to ₹443 crores and EBITDA increasing 26.3% to ₹128 crores, driven by robust surgical volumes and strategic expansion. The company added 42 new facilities year-to-date and plans further additions in Q4 FY25, while maintaining EBITDA margins despite aggressive growth. Challenges included increased doctor costs and a one-time marketing expense, but the overall outlook remains positive.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 255 | 268 |
| EBITDA | 58 | 65 |
| Net profit | -4 | 8 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
